Page 31 - Read Online

Page 8 of 8 Gavriilidis et al. Hepatoma Res 2023;9:23 https://dx.doi.org/10.20517/2394-5079.2023.26

cholangiocarcinoma: a systematic review. J Gastrointest Surg 2014;18:2136-48. DOI PubMed
12. de Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of
prognostic factors and lymph node assessment. J Clin Oncol 2011;29:3140-5. DOI PubMed
13. Zhang XF, Chakedis J, Bagante F, et al. Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic
cholangiocarcinoma. Br J Surg 2018;105:857-66. DOI
14. Zhang XF, Xue F, Dong DH, et al. Number and station of lymph node metastasis after curative-intent resection of intrahepatic
cholangiocarcinoma impact prognosis. Ann Surg 2021;274:e1187-95. DOI PubMed
15. Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-
based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67:93-9. DOI PubMed
16. Bagante F, Spolverato G, Weiss M, et al. Assessment of the lymph node status in patients undergoing liver resection for
intrahepatic cholangiocarcinoma: the new eighth edition AJCC staging system. J Gastrointest Surg 2018;22:52-9. DOI
17. van den Bent L, Frenkel NC, Poghosyan S, et al. Liver lymphatic drainage patterns follow segmental anatomy. Br J Surg
2022;109:559-60. DOI
18. Jeong J, Tanaka M, Iwakiri Y. Hepatic lymphatic vascular system in health and disease. J Hepatol 2022;77:206-18. DOI PubMed
PMC
19. Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for
gastric cancer. Br J Surg 1995;82:346-51. DOI PubMed
20. Sahara K, Tsilimigras DI, Merath K, et al. Therapeutic index associated with lymphadenectomy among patients with intrahepatic
cholangiocarcinoma: which patients benefit the most from nodal evaluation? Ann Surg Oncol 2019;26:2959-68. DOI
21. Farges O, Fuks D, Boleslawski E, et al. Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a
multicenter study by the AFC-IHCC-2009 study group. Ann Surg 2011;254:824-29; discussion 830. DOI
22. Valle J, Wasan H, Palmer DH, et al; ABC-02 trial investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
N Engl J Med 2010;362:1273-81. DOI
23. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-
704. DOI
24. Neoptolemos JP, Palmer DH, Ghaneh P, et al; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and
capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label,
randomised, phase 3 trial. Lancet 2017;389:1011-24. DOI PubMed
25. Primrose JN, Fox RP, Palmer DH, et al; BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer
(BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663-73. DOI PubMed
26. Cloyd JM, Ejaz A, Pawlik TM. The landmark series: intrahepatic cholangiocarcinoma. Ann Surg Oncol 2020;27:2859-65. DOI
PubMed
27. Nakachi K, Ikeda M, Konishi M, et al; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-
HBPOG). Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label,
randomised, controlled, phase 3 trial. Lancet 2023;401:195-203. DOI PubMed
28. Bressler L, Bath N, Manne A, Miller E, Cloyd JM. Management of locally advanced intrahepatic cholangiocarcinoma: a narrative
review. Chin Clin Oncol 2023;12:15. DOI PubMed
29. Ziogas IA, Giannis D, Economopoulos KP, et al. Liver Transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-
regression of survival rates. Transplantation 2021;105:2263-71. DOI
30. Sapisochin G, Facciuto M, Rubbia-Brandt L, et al; iCCA International Consortium. Liver transplantation for “very early” intrahepatic
cholangiocarcinoma: international retrospective study supporting a prospective assessment. Hepatology 2016;64:1178-88. DOI
PubMed
31. Lunsford KE, Javle M, Heyne K, et al; Methodist–MD Anderson Joint Cholangiocarcinoma Collaborative Committee (MMAJCCC).
Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.
Lancet Gastroenterol Hepatol 2018;3:337-48. DOI
32. Mauro E, Ferrer-Fàbrega J, Sauri T, et al. New challenges in the management of cholangiocarcinoma: the role of liver transplantation,
locoregional therapies, and systemic therapy. Cancers 2023;15:1244. DOI PubMed PMC
33. Ruff SM, Shannon AH, Pawlik TM. Advances in targeted immunotherapy for hepatobiliary cancers. Int J Mol Sci 2022;23:13961.
DOI PubMed PMC
34. Ruff SM, Shannon AH, Beane JD, Pawlik TM. Highlighting novel targets in immunotherapy for liver cancer. Expert Rev
Gastroenterol Hepatol 2022;16:1029-41. DOI PubMed
35. Cadamuro M, Brivio S, Mertens J, et al. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor
lymphangiogenesis in cholangiocarcinoma. J Hepatol 2019;70:700-9. DOI
36. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401. DOI PubMed
37. Compton CC, Byrd DR, Garcia-Aguilar J. Intrahepatic bile ducts. In: AJCC Cancer Staging Atlas. Springer; 2012.